Synthekine

Synthekine announced that updated clinical and translational data from a Phase 1a/1b trial of STK-012 would be presented at the American Association for Cancer Research Annual Meeting 2026.

Synthekine announced a clinical trial collaboration and supply agreement with Merck to evaluate STK-012 in combination with standard-of-care chemotherapy and Keytruda.

Synthekine Inc., an engineered cytokine therapeutics company, appointed John A. Orwin as Chair of its Board of Directors. Orwin succeeds Srinivas Akkaraju, M.D., Ph.D., who will remain an active Board member.

Synthekine says its open mindset, including questioning established ideas and re-examining data, supports its work to discover and develop medicines.

Anita has served as Synthekine’s Vice President of Translational and Bioanalytical Sciences since February 2023, after serving as Senior Director and Head of Bioanalytical Sciences. She has more than 25 years of experience and has partnered with over 100 companies globally.

Iris has served as Synthekine’s Vice President of Clinical Development Operations since January 2026. Iris has 20 years of experience across small biotech, Big Pharma, CROs, academic institutions, and private practice, with expertise in global clinical trial operations.

Naiyer has served as Synthekine’s Chief Medical Officer since May 2021. Naiyer’s clinical research helped deliver FDA approvals of nivolumab in squamous lung cancer and pembrolizumab in non-small cell lung cancer.

A company applying distinct protein engineering platforms to develop immunotherapies designed to unlock the full efficacy potential of cytokines while avoiding toxicities associated with their pleiotropy.

The company focuses on discovering, developing, and commercializing selective cytokine therapeutics. It says these therapies could change treatment of cancer and inflammatory disease.

Synthekine’s Privacy Notice explains how the company collects, uses, and shares personal data. Synthekine says it does not sell personal data or use it for purposes beyond those described in the notice.